For World Inflammatory Bowel Disease day we spoke to Pfizer’s Matt Shaulis, president of international developed markets for inflammation and immunology, to hear how the company hopes to ha
This week saw some mixed news in coronavirus research as questions were raised about access to COVID-19 drugs as studies – and approvals – continued apace.
With trial delays, social distancing, and falls in charitable funding, the coronavirus pandemic presents some serious challenges for nonprofit orphan disease biotechs like Cure Rare Disease
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.